Cambridge, MA, United States of America

Thomas Schurpf

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 143(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents

Title: Inventor Thomas Schurpf: Pioneering Advances in TGFβ Inhibition

Introduction

Thomas Schurpf, based in Cambridge, Massachusetts, is a distinguished inventor with a robust portfolio of 14 patents. He has made significant contributions to the field of biotechnology, particularly in the development of inhibitors targeting TGFβ, which are crucial in addressing various fibrotic conditions and related disorders.

Latest Patents

Schurpf's latest patents include innovative breakthroughs such as "LTBP complex-specific inhibitors of TGFβ and uses thereof." This patent discloses inhibitors like antibodies that selectively bind to complexes of LTBP1-TGFβ and LTBP3-TGFβ. It provides methods aimed at inhibiting TGFβ activation, offering potential treatments for individuals suffering from TGFβ-related disorders, including fibrotic conditions. Another notable patent is "Isoform-selective TGFB1 inhibitors and use thereof," which details monoclonal antibodies capable of selectively inhibiting TGFβ1 with remarkable potency, alongside related compositions and therapeutic applications.

Career Highlights

Throughout his career, Thomas Schurpf has played a pivotal role in advancing therapeutic strategies. His dedication to biotechnology is exemplified by his work at Scholar Rock, Inc., where he has been integral to the development of cutting-edge treatments targeting TGFβ.

Collaborations

Schurpf collaborates with esteemed colleagues such as Nagesh K Mahanthappa and Michelle Marie Straub. Together, they push the envelope in therapeutic innovation, contributing to the company's mission of addressing complex medical challenges through targeted inhibition.

Conclusion

Thomas Schurpf stands out as a leading figure in the biotech industry, with a focus on TGFβ inhibition that holds promise for treating fibrotic conditions and related disorders. His innovative patents and collaboration with talented professionals highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…